Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.

The recent crystal structure determinations of druggable class A G protein-coupled receptors (GPCRs) have opened up excellent opportunities in structure-based ligand discovery for this pharmaceutically important protein family. We have developed and validated a customized structure-based virtual fragment screening protocol against the recently determined human histamine H(1) receptor (H(1)R) crystal structure. The method combines molecular docking simulations with a protein-ligand interaction fingerprint (IFP) scoring method. The optimized in silico screening approach was successfully applied to identify a chemically diverse set of novel fragment-like (≤22 heavy atoms) H(1)R ligands with an exceptionally high hit rate of 73%. Of the 26 tested fragments, 19 compounds had affinities ranging from 10 μM to 6 nM. The current study shows the potential of in silico screening against GPCR crystal structures to explore novel, fragment-like GPCR ligand space.

[1]  Didier Rognan,et al.  Fragment-based approaches and computer-aided drug discovery. , 2012, Topics in current chemistry.

[2]  Krzysztof Palczewski,et al.  The Significance of G Protein-Coupled Receptor Crystallography for Drug Discovery , 2011, Pharmacological Reviews.

[3]  Ruben Abagyan,et al.  GPCR agonist binding revealed by modeling and crystallography. , 2011, TIPS - Trends in Pharmacological Sciences.

[4]  R. Smits,et al.  Fragment library screening reveals remarkable similarities between the G protein-coupled receptor histamine H4 and the ion channel serotonin 5-HT3A , 2011, Bioorganic & medicinal chemistry letters.

[5]  Ruben Abagyan,et al.  Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment. , 2011, Structure.

[6]  Avner Schlessinger,et al.  Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure , 2011, Nature chemical biology.

[7]  Ruben Abagyan,et al.  Structure of the human histamine H1 receptor complex with doxepin , 2011, Nature.

[8]  Jean-Louis Reymond,et al.  Visualisation and subsets of the chemical universe database GDB-13 for virtual screening , 2011, J. Comput. Aided Mol. Des..

[9]  Jonathan S. Mason,et al.  Progress in Structure Based Drug Design for G Protein-Coupled Receptors , 2011, Journal of medicinal chemistry.

[10]  Didier Rognan,et al.  Docking Methods for Virtual Screening: Principles and Recent Advances , 2011 .

[11]  S. Rasmussen,et al.  Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.

[12]  Erica Westly Nothing to sneeze at , 2010, Nature Medicine.

[13]  Mathias Wawer,et al.  Similarity-Potency Trees: A Method to Search for SAR Information in Compound Data Sets and Derive SAR Rules , 2010, J. Chem. Inf. Model..

[14]  Wen Jiang,et al.  Molecular Determinants of Ligand Binding to H4R Species Variants , 2010, Molecular Pharmacology.

[15]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[16]  Brian K. Shoichet,et al.  Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.

[17]  Ruben Abagyan,et al.  Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.

[18]  Didier Rognan,et al.  Customizing G Protein-coupled receptor models for structure-based virtual screening. , 2009, Current pharmaceutical design.

[19]  Thomas M Frimurer,et al.  A Conserved Aromatic Lock for the Tryptophan Rotameric Switch in TM-VI of Seven-transmembrane Receptors* , 2009, The Journal of Biological Chemistry.

[20]  A. Brown,et al.  Optimising metabolic stability in lipophilic chemical space: the identification of a metabolically stable pyrazolopyrimidine CRF-1 receptor antagonist. , 2009, Bioorganic & medicinal chemistry letters.

[21]  Jason C. Cole,et al.  Testing Assumptions and Hypotheses for Rescoring Success in Protein-Ligand Docking , 2009, J. Chem. Inf. Model..

[22]  Rob Leurs,et al.  Transforming fragments into candidates: small becomes big in medicinal chemistry. , 2009, Drug discovery today.

[23]  Sid Topiol,et al.  X-ray structure breakthroughs in the GPCR transmembrane region. , 2009, Biochemical pharmacology.

[24]  S. Rasmussen,et al.  The structure and function of G-protein-coupled receptors , 2009, Nature.

[25]  Peter Kolb,et al.  Structure-based discovery of β2-adrenergic receptor ligands , 2009, Proceedings of the National Academy of Sciences.

[26]  Andreas Evers,et al.  Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening. , 2009, Journal of medicinal chemistry.

[27]  Wendy A. Warr,et al.  ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI) , 2009, J. Comput. Aided Mol. Des..

[28]  Thierry Kogej,et al.  Comparison of Molecular Fingerprint Methods on the Basis of Biological Profile Data , 2009, J. Chem. Inf. Model..

[29]  Thomas Stützle,et al.  Empirical Scoring Functions for Advanced Protein-Ligand Docking with PLANTS , 2009, J. Chem. Inf. Model..

[30]  The identification of neurotensin NTS1 receptor partial agonists through a ligand-based virtual screening approach. , 2008, Bioorganic & medicinal chemistry letters.

[31]  Kenneth Jones,et al.  Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. , 2008, Bioorganic & medicinal chemistry letters.

[32]  D. Rognan,et al.  Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. , 2008, Journal of medicinal chemistry.

[33]  Béla Noszál,et al.  Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. , 2008, Journal of medicinal chemistry.

[34]  Chris G. Kruse,et al.  Assessment of scaffold hopping efficiency by use of molecular interaction fingerprints. , 2008, Journal of medicinal chemistry.

[35]  R. Gillespie,et al.  Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines. , 2008, Bioorganic & medicinal chemistry letters.

[36]  Didier Rognan,et al.  Ranking Targets in Structure-Based Virtual Screening of Three-Dimensional Protein Libraries: Methods and Problems , 2008, J. Chem. Inf. Model..

[37]  H. Schiöth,et al.  Structural diversity of G protein-coupled receptors and significance for drug discovery , 2008, Nature Reviews Drug Discovery.

[38]  Stefano Costanzi,et al.  A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antagonists. , 2008, Journal of the American Chemical Society.

[39]  Ajay N. Jain,et al.  Recommendations for evaluation of computational methods , 2008, J. Comput. Aided Mol. Des..

[40]  Stefano Costanzi,et al.  Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. , 2008, Journal of medicinal chemistry.

[41]  Claudio N. Cavasotto,et al.  Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. , 2008, Journal of medicinal chemistry.

[42]  Jan Schultz,et al.  Integration of fragment screening and library design. , 2007, Drug discovery today.

[43]  Vladimir Sobolev,et al.  Target specific virtual screening: optimization of an estrogen receptor screening platform. , 2007, Journal of medicinal chemistry.

[44]  Thomas Stützle,et al.  An ant colony optimization approach to flexible protein–ligand docking , 2007, Swarm Intelligence.

[45]  R. Leurs,et al.  In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs as Inverse H1 Receptor Agonists , 2007, Journal of Pharmacology and Experimental Therapeutics.

[46]  E. Kellenberger,et al.  Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. , 2007, Journal of medicinal chemistry.

[47]  Gilles Marcou,et al.  Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints , 2007, J. Chem. Inf. Model..

[48]  Raphael Nudelman,et al.  An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. , 2006, Journal of medicinal chemistry.

[49]  Cathy H. Wu,et al.  The Universal Protein Resource (UniProt): an expanding universe of protein information , 2005, Nucleic Acids Res..

[50]  Didier Rognan,et al.  A chemogenomic analysis of the transmembrane binding cavity of human G‐protein‐coupled receptors , 2005, Proteins.

[51]  Rob Leurs,et al.  Keynote review: histamine H3 receptor antagonists reach out for the clinic. , 2005, Drug discovery today.

[52]  Tudor I. Oprea,et al.  Integration of Virtual Screening with High-Throughput Flow Cytometry to Identify Novel Small Molecule Formylpeptide Receptor Antagonistss⃞ , 2005, Molecular Pharmacology.

[53]  Antti Poso,et al.  Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor. , 2005, Journal of medicinal chemistry.

[54]  L. Pardo,et al.  Linking agonist binding to histamine H1 receptor activation , 2005, Nature chemical biology.

[55]  T. Klabunde,et al.  Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. , 2005, Journal of medicinal chemistry.

[56]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[57]  G. Klebe,et al.  Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. , 2004, Journal of medicinal chemistry.

[58]  D. E. Clark,et al.  A virtual screening approach to finding novel and potent antagonists at the melanin-concentrating hormone 1 receptor. , 2004, Journal of medicinal chemistry.

[59]  D. J. Price,et al.  Assessing scoring functions for protein-ligand interactions. , 2004, Journal of medicinal chemistry.

[60]  R. Leurs,et al.  Mutational analysis of the histamine H1-receptor binding pocket of histaprodifens. , 2004, European journal of pharmacology.

[61]  Xueliang Fang,et al.  Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. , 2003, Journal of medicinal chemistry.

[62]  Jun Xu A new approach to finding natural chemical structure classes. , 2002, Journal of medicinal chemistry.

[63]  R. Leurs,et al.  H1‐antihistamines: inverse agonism, anti‐inflammatory actions and cardiac effects , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[64]  M. Gillard,et al.  Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194). , 2002, Molecular pharmacology.

[65]  Lei Shi,et al.  The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. , 2002, Annual review of pharmacology and toxicology.

[66]  R. Leurs,et al.  Mutational Analysis of the Antagonist-binding Site of the Histamine H1 Receptor* , 1999, The Journal of Biological Chemistry.

[67]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[68]  H Hayashi,et al.  Site-directed mutagenesis of the histamine H1 receptor: roles of aspartic acid107, asparagine198 and threonine194. , 1994, Biochemical and biophysical research communications.

[69]  S. Takai,et al.  Molecular cloning of the human histamine H1 receptor gene. , 1994, Biochemical and biophysical research communications.

[70]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.